Pfizer Depo-subQ Provera 104 Will Launch In May With Endometriosis Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
The new formulation has greater contraceptive efficacy and less hormone than Depo-Provera, Pfizer says. Labeling carries "black box" warnings on loss of bone mineral density; Pfizer notes that, in clinical trials, depo-subQ provera 104 had less decrease in BMD than endometriosis-pain comparator Lupron Depot.